Clinical trials: Nervous System Disorders
Sleep Apnea
A Validation Study of the NightOwl PAT-based Home Sleep Apnea Test
The objective of this study is to evaluate the performance of a miniaturized sleep apnea test, called NightOwl. The system consists of a sensor placed on the fingertip and a cloud-based analytics software.
- Trial name
- NCT04191668
- Testing
- NightOwl
- Where
- 3 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Ectosense NV
Phenylketonuria (PKU)
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the…
- Trial name
- PALace (NCT05813678)
- Testing
- Pegvaliase
- Where
- 26 sites in United States, Germany and 1 more
- Volunteers
- 450 people
- Sponsor
- BioMarin Pharmaceutical
Diphtheria, Tetanus
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722) and booster vaccination in Study A3L27 (NCT01444781).
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01983540
- Testing
- DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine, DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine, Infanrix hexa + Prevenar + Rotarix vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Phenylketonurias
Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels
The primary objective of this study is to evaluate the efficacy of Phenoptin™ (sapropterin dihydrochloride) in reducing blood phenylalanine (Phe) levels in subjects with phenylketonuria.
- Trial name
- NCT00104247
- Testing
- sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- BioMarin Pharmaceutical
Chronic Migraine, Episodic Migraine
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Conditions
- Chronic Migraine, Episodic Migraine, Migraine
- Trial name
- Atogepant PMSS (NCT06603558)
- Testing
- Atogepant
- Where
- 36 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- AbbVie
Behavioral Variant Frontotemporal Dementia (bvFTD)
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the treatment of patients with behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NCT01626378
- Testing
- TRx0237
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- TauRx Therapeutics Ltd
Retinitis Pigmentosa (RP)
Retrospective Natural History Study of Retinitis Pigmentosa
This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6A or PDE6B gene mutations.
- Trial name
- PHENOROD1 (NCT03975543)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- SparingVision
Sleep Apnea - Obstructive
A Study of the Sleepnet Elara APAP Device
The goal of this study is to evaluate the effectiveness of the Elara APAP device.
- Trial name
- NCT07559708
- Testing
- Sleepnet Elara Treatment
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sleepnet Corporation
Acute Ischemic Stroke, Vessel Occlusion
REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.
- Conditions
- Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic
- Trial name
- "RESTORE" (NCT04451525)
- Testing
- MicroVention Mechanical Thrombectomy Devices as first-line treatment
- Where
- 37 sites in United States
- Volunteers
- 710 people
- Sponsor
- Microvention-Terumo, Inc.
Duchenne Muscular Dystrophy
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participants receiving eteplirsen…
- Trial name
- EVOLVE (NCT06606340)
- Testing
- Eteplirsen, Golodirsen, Casimersen
- Where
- 23 sites in United States
- Volunteers
- 300 people
- Sponsor
- Sarepta Therapeutics, Inc.
Insomnia
Safety of Ramelteon in Elderly Subjects
The purpose of this study is to investigate the effects of ramelteon in elderly subjects on balance, mobility and memory impairment after awakening in the middle of the night following bedtime dosing.
- Trial name
- NCT00568789
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Takeda
Acute Stroke
Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke
This study is a first-in-human assessment of safety of using umbilical cord mesenchymal stem cells (UCMSCs) in patients with Acute Ischemic Stroke via a combination of intra arterial (IA) and intravenous (IV) stem cell…
- Trial name
- NCT04434768
- Testing
- UMSC01
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
OSA - Obstructive Sleep Apnea, Obesity
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
- Trial name
- NCT07434050
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obstructive Sleep Apnoea (OSA)
Feasibility of Upper Airway Stimulation in OSA
Project Breathe 1 is a short-duration (5 month) pilot investigation to assess the safety and tolerability of non-invasive electrical stimulation in adults with obstructive sleep apnoea.
- Trial name
- NCT07396649
- Testing
- Non-invasive electrical stimulation
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Notos Medical Limited
Anesthesia, Anesthesia, Local
A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade
Neosaxitoxin is a new compound that is in clinical development as local anesthetic for surgical anesthesia and postoperative analgesia.
- Conditions
- Anesthesia, Anesthesia, Local, Analgesia
- Trial name
- NCT03399435
- Testing
- Neosaxitoxin combined with bupivacaine low and epinephrine (T1), Bupivacaine low combined with epinephrine (C1), Bupivacaine high combined with epinephrine (C2)
- Where
- Netherlands
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Phenylketonuria
A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
Sapropterin dihydrochloride (subsequently referred to as sapropterin) (Kuvan®) was approved by the FDA for the treatment of hyperphenylalaninemia in 2007.
- Trial name
- NCT00789568
- Testing
- sapropterin dihydrochloride, Moxifloxacin
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- BioMarin Pharmaceutical
Tuberculosis Meningitis
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity.
- Trial name
- NCT07350174
- Testing
- HRZE, HRZE plus Alpe375, HRZE plus AlpE500
- Volunteers
- 64 people
- Sponsor
- BioVersys AG
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Multiple Sclerosis, Relapsing Multiple Sclerosis
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
- Conditions
- Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
- Trial name
- EXCHANGE (NCT03623243)
- Testing
- Siponimod
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
To assess the long-term effects of levetiracetam on retention rate in subjects with refractory partial onset seizure that are not fully controlled with 1 to 3 concomitant antiepileptic drugs, compared to topiramate as add-on…
- Trial name
- NCT01229735
- Testing
- Levetiracetam, Topiramate
- Where
- 24 sites in South Korea
- Volunteers
- 343 people
- Sponsor
- UCB Korea Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.